Envoy Medical, Inc. (COCH) - Q2 2024 10-Q Summary
Business Context and Reporting Period
Envoy Medical, Inc. is a hearing health company focused on fully implanted hearing devices. The reporting period covers the three and six months ended June 30, 2024. The Company's primary commercial product is the Esteem Fully Implanted Active Middle Ear Implant (FI-AMEI), while its lead product candidate, the Acclaim Cochlear Implant (CI), is in development and has received FDA Breakthrough Device Designation. The Company completed a business combination with Anzu Special Acquisition Corp I in September 2023.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Net Revenues | $68 | $63 | $127 | $141 |
| Net Loss | $(3,947) | $(13,246) | $(10,217) | $(26,499) |
| Net Loss Attributable to Common Stockholders | $(5,312) | $(13,246) | $(12,947) | $(26,499) |
| Cash and Cash Equivalents (End of Period) | $1,746 | $68 | $1,746 | $68 |
| Total Liabilities | $19,124 | N/A | $19,124 | N/A |
| Stockholders' Deficit | $(12,387) | N/A | $(12,387) | N/A |
Debt and Liquidity: As of June 30, 2024, the Company held $1.7 million in cash. Total liabilities increased significantly to $19.1 million, driven by a $7.3 million related-party term loan (2024 Term Loan) and accrued expenses of $6.0 million. The Company has an accumulated deficit of $270.2 million.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased significantly year-over-year (Q2 2024: $3.9M vs. Q2 2023: $13.2M). This improvement is primarily due to the absence of an $8.8 million loss from changes in fair value of convertible notes payable in 2024, which were converted to equity in the September 2023 business combination.
- Revenue: Net revenues were relatively flat, increasing slightly by $5,000 in Q2 2024 compared to Q2 2023, but decreased by $14,000 on a year-to-date basis due to supply chain issues affecting battery replacement sales.
- Operating Expenses: Research and Development (R&D) expenses increased by 20.3% in Q2 2024 ($2.6M) compared to the prior year, driven by increased headcount and contractors in preparation for the Acclaim CI pivotal clinical study. General and Administrative (G&A) expenses decreased by 13.6% in Q2 2024 due to reduced professional fees related to the 2023 merger closing.
- Financing Activity: The Company drew $7.5 million from a related-party term loan during the first six months of 2024 and received $1.7 million from the sale of common stock associated with a forward purchase agreement.
Guidance, Outlook, and Risks
- Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern. While they believe existing cash and future capital raises will fund operations for at least one year, there is no assurance of success in achieving strategic plans or securing additional financing.
- Product Development: The Company submitted an Investigational Device Exemption (IDE) application for the Acclaim CI in Q1 2024 but converted it to a "pre-submission" to allow for further FDA interaction. They anticipate re-submitting the IDE in Q3 or Q4 2024 and aim for FDA Premarket Approval (PMA) by the end of 2026.
- Legal Proceedings: The Company is defending a lawsuit filed by Atlas Merchant Capital SPAC Fund I LP alleging breach of fiduciary duty and other claims related to the business combination redemption process. The Company believes the claims are meritless.
- Internal Controls: Management identified material weaknesses in internal control over financial reporting, including insufficient accounting personnel, lack of formal risk assessment, and ineffective IT general controls. Remediation efforts are ongoing.
- Preferred Stock Dividends: The Company has accrued $2.9 million in unpaid dividends on Series A Preferred Stock as of June 30, 2024, due to insufficient net tangible assets to trigger payment requirements under the Sponsor Support Agreement.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.7 million cash balance against the burn rate and the likelihood of securing additional capital given the "substantial doubt" disclosure.
- Related Party Debt: Review the terms of the $7.3 million related-party term loan, including interest rates, maturity (2029), and the associated warrant issuance requirements.
- Acclaim CI Timeline: Monitor the status of the IDE re-submission and FDA interactions, as delays could significantly impact the projected 2026 approval timeline.
- Internal Control Remediation: Assess the progress of remediation plans for the identified material weaknesses in financial reporting and IT controls.
- Legal Exposure: Track the outcome of the Atlas Merchant Capital litigation, which seeks approximately $9.4 million in damages.